Eupatilin

Catalog No.S3846 Synonyms: NSC 122413

For research use only.

Eupatilin (NSC 122413), a major flavonoid from Artemisia plants, possesses various beneficial biological effects including anti-inflammation, anti-tumor, anti-cancer, anti-allergy, and anti-oxidation activity. Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.

Eupatilin Chemical Structure

CAS No. 22368-21-4

Selleck's Eupatilin has been cited by 1 Publication

Purity & Quality Control

Choose Selective PPAR Inhibitors

Other PPAR Products

Biological Activity

Description Eupatilin (NSC 122413), a major flavonoid from Artemisia plants, possesses various beneficial biological effects including anti-inflammation, anti-tumor, anti-cancer, anti-allergy, and anti-oxidation activity. Eupatilin, a lipophilic flavonoid isolated from Artemisia species, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
In vitro

Eupatilin has been reported to induce apoptosis in human gastric cancer AGS cells, also triggers differentiation of these cells. Treatment of AGS cells with eupatilin induces cell cycle arrest at the G1 phase with the concomitant induction of p21cip1, a cell cycle inhibitor. It also markedly induces trefoil factor1(TFF1). Eupatilin dramatically induces redistribution of tight junction proteins such as occludin and ZO-1, and F-actin at the junctional region between cells. It also induces phosphorylation of extracellular signal-regulated kinase 2 and p38 kinase. Eupatilin is known to inhibit the growth of MCF-10A-ras cells by inhibiting the expression of cell cycle regulators such as cyclinD1, cyclinB1, Cdk2, and Cdc2[1].

In vivo Treatment with eupatilin significantly decreases serum alanine aminotransferase and serum aspartate aminotransferase as well as liver histologic changes. Eupatilin also preventes hepatic glutathione depletion and increases malondialdehyde levels induced by Ischemia-reperfusion injury (IRI). It improves the acute hepatic IRI by reducing inflammation and apoptosis[2]. Oral administration of eupatilin (10 mg/kg) in a therapeutic paradigm significantly reduces brain infarction and improves neurological functions in tMCAO-challenged mice. Eupatilin administration reduces the number of Iba1-immunopositive cells across ischemic brain and induces their morphological changes from amoeboid into ramified in the ischemic core, which is accompanied with reduced microglial proliferation in ischemic brain. Eupatilin suppresses NF-κB signaling activities in ischemic brain by reducing IKKα/β phosphorylation, IκBα phosphorylation, and IκBα degradation[3].

Protocol (from reference)

Cell Research:[1]
  • Cell lines: Human gastric epithelial AGS cells
  • Concentrations: 10-500 μM
  • Incubation Time: 24, 48, 72 h
  • Method: Cellular viability is determined by PI incorporation. Cells are treated with various reagents, washed with PBS twice, resuspended in PBS containing 20 μg/ml PI, and then immediately analyzed on a FACSCalibur. PI-positive cells are counted as dead cells and the remaining cells are designated as viable cells.
Animal Research:[2]
  • Animal Models: C57BL/6 mice
  • Dosages: 10 mg/kg
  • Administration: oral

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 344.32
Formula

C18H16O7

CAS No. 22368-21-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)OC)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Eupatilin | Eupatilin supplier | purchase Eupatilin | Eupatilin cost | Eupatilin manufacturer | order Eupatilin | Eupatilin distributor